Publications
- Anti-NMDAR Antibodies in Demyelinating Diseases2017 | Second Faculty of Medicine, Third Faculty of Medicine
- Alemtuzumab in multiple sclerosis treatment2015 | Second Faculty of Medicine
- Management of psoriasis vulgaris and multiple sclerosis with fumaric acid2014 | Second Faculty of Medicine, Third Faculty of Medicine
- Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study2012 | Second Faculty of Medicine
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis2012 | Second Faculty of Medicine
- Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study2012 | Second Faculty of Medicine
- Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis2012 | Second Faculty of Medicine
- BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis2011 | Second Faculty of Medicine
- Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study2010 | Second Faculty of Medicine
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis2010 | Second Faculty of Medicine
Loading network view...